Naglaa Allam

Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial

Imam Waked, Gamal Shiha, Roula Qaqish et al. · ˜The œLancet. Gastroenterology & hepatology · 2016 · 74 citations

Medicine, Infectious Diseases, Pharmacotherapy +16

Platelet-albumin-bilirubin score - a predictor of outcome of acute variceal bleeding in patients with cirrhosis

Omar Elshaarawy, Naglaa Allam, Eman Abdelsameea et al. · World Journal of Hepatology · 2020 · 37 citations · Full text

Medicine, Hematology, Hemostasis +16

Clinical Outcomes for Saudi and Egyptian Patients Receiving Deceased Donor Liver Transplantation in China

Naglaa Allam, Mohammed Al Saghier, Yasser El Sheikh et al. · American Journal of Transplantation · 2010 · 31 citations · Full text

Medicine, Surgery, Hepatology +14

Study of adiponectin in chronic liver disease and cholestasis

Tary Salman, Naglaa Allam, Gasser El-Azab et al. · Hepatology International · 2010 · 30 citations · Full text

Medicine, Biochemistry, Internal Medicine +11

Effectiveness of ravidasvir plus sofosbuvir in interferon-naïve and treated patients with chronic hepatitis C genotype-4

Gamal Esmat, Tamer Elbaz, Asmaa Gomaa et al. · Journal of Hepatology · 2017 · 23 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +14